Oxybutynin: here's the fair price
This is what US pharmacies pay, on average, for oxybutynin. Use it to spot a fair cash price, and feel good about asking for one.
Oxybutynin 5 Mg Tablet
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Oxybutynin 5 Mg Tablet. Pharmacies pay about $1.46 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| OXYBUTYNIN 5 MG/5 ML SOLUTIONGeneric | $0.03 per mL | n/a | 10/21/2026 |
| OXYBUTYNIN 5 MG/5 ML SYRUPGeneric | $0.03 per mL | n/a | 10/21/2026 |
| OXYBUTYNIN 5 MG TABLETGeneric | $0.05 per tablet or capsule | $1.46 | 10/21/2026 |
| OXYBUTYNIN CL ER 5 MG TABLETGeneric | $0.09 per tablet or capsule | $2.56 | 10/21/2026 |
| OXYBUTYNIN CL ER 10 MG TABLETGeneric | $0.10 per tablet or capsule | $3.00 | 10/21/2026 |
| OXYBUTYNIN CL ER 15 MG TABLETGeneric | $0.13 per tablet or capsule | $3.86 | 10/21/2026 |
| OXYBUTYNIN 2.5 MG TABLETGeneric | $1.82 per tablet or capsule | $54.55 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
1 INDICATIONS AND USAGE Oxybutynin chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ( 1 ) Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended release tablets are also indicated for the...
Common side effects (FDA label)
6 ADVERSE REACTIONS The most common (incidence ≥5%) adverse reactions were dry mouth, constipation, diarrhea, headache, somnolence and dizziness. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical...
Drug interactions (from the label)
7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. ( 7 ) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. ( 7 ) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal...
Warnings (from the label)
5 WARNINGS AND PRECAUTIONS Angioedema: Angioedema has been reported with oxybutynin. If symptoms of angioedema occur, discontinue oxybutynin chloride extended-release tablets immediately and initiate appropriate therapy. ( 5.1 ) Central Nervous System (CNS) effects: CNS effects have been reported with oxybutynin. If patient experiences anticholinergic CNS effects, consider dose adjustment or discontinuation of oxybutynin chloride extended-release tablets. ( 5.2 ) Use with caution due to aggravation of symptoms: ○ Pre-existing dementia in patients treated with cholinesterase inhibitors ( 5.2 ), ○ Parkinson's disease ( 5.2 ), ○ Myasthenia gravis ( 5.3 ), and ○ Decreased gastrointestinal...
Source: FDA drug label via openFDA, label effective 2023-02-06. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.